The Prostate Centre's Translational Research Initiative for Accelerated Discovery and Development PC-TRIADD integrates within one organization the critical components of the complex processes involved in adapting discoveries from the laboratory to the patient's bedside. The Centre acts as a bridge between academia and the biotechnology and pharmaceutical industries, facilitating rapid progression of new drug treatments into human trials, promoting regional growth and investment in biotechnology, and improving patient care.

PC-TRIADD has created intellectual property and licensed eight drug products to three local biotech companies, all of which were spun-off from the Prostate Centre. While PC-TRIADD focuses on prostate cancer, many of its services and discoveries can be applied to other cancers, including breast, lung, colon and bladder.

The Prostate Centre's Translational Research Initiative for Accelerated Discovery and Development - PC-TRIADD (2008-2013)
Focus:	To foster the paradigm of team-driven translational health research to discover molecular mechanisms of cancer progression and therapeutic resistance, and to use this information to develop new services and products that reduce suffering, improve survival for patients with cancer and promote regional growth of biotechnology.
Funding:	$14.95 million for entire funding period
Strength:	11 patents issued 1 license under negotiation
Partnership Power:	$1,170,393 in partner cash $20,157 in in-kind support 28 graduate students trained, 23 postdoctoral students trained
Centre Director:	Dr. Martin Gleave
Web site:	www.prostatecentre.com